Kurt J. Andrews Net Worth

The estimated Net Worth of Kurt J. Andrews is at least $3.56 Million dollars as of 2 July 2018. Kurt Andrews owns over 5,000 units of Immunomedics stock worth over $3,555,606 and over the last 9 years Kurt sold IMMU stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Kurt Andrews IMMU stock SEC Form 4 insiders trading

Kurt has made over 3 trades of the Immunomedics stock since 2018, according to the Form 4 filled with the SEC. Most recently Kurt exercised 5,000 units of IMMU stock worth $30,650 on 2 July 2018.

The largest trade Kurt's ever made was exercising 10,000 units of Immunomedics stock on 2 January 2018 worth over $147,200. On average, Kurt trades about 1,818 units every 16 days since 2016. As of 2 July 2018 Kurt still owns at least 40,469 units of Immunomedics stock.

You can see the complete history of Kurt Andrews stock trades at the bottom of the page.

What's Kurt Andrews's mailing address?

Kurt's mailing address filed with the SEC is C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS, NJ, 07950.

Insiders trading at Immunomedics

Over the last 21 years, insiders at Immunomedics have traded over $5,318,095 worth of Immunomedics stock and bought 12,330,539 units worth $195,802,181 . The most active insiders traders include Capital Advisors Llc Aghaza..., David M Goldenberg, and Cynthia L Goldenberg. On average, Immunomedics executives and independent directors trade stock every 105 days with the average trade being worth of $27,159,459. The most recent stock trade was executed by Barbara Gayle Duncan on 14 September 2020, trading 2,500 units of IMMU stock currently worth $42,400.

What does Immunomedics do?

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Complete history of Kurt Andrews stock trades at Amicus Therapeutics Inc and Immunomedics

Immunomedics executives and stock owners

Immunomedics executives and other stock owners filed with the SEC include:

• Behzad Avoro Capital Adviso...,
  
• Geoffrey F Cox,
  Director
• Robert Forrester,
  Director
• Jason Aryeh,
  Director
• Harout Semerjian,
  President and CEO
• Bob Oliver,
  Director
• Marvin Jaffe,
  Director
• Michael F. Pehl,
  President and CEO
• Capital Advisors Llc Aghaza...,
  
• Peter Barton Hutt,
  Director
• Scott A Canute,
  Director
• Khalid Islam,
  Director
• Michael Garone,
  CHIEF FINANCIAL OFFICER
• Brian A Markison,
  Director
• Behzad Aghazadeh,
  Director
• Select Advisor Llc Ven Bio,
  Director
• Robert Iannone,
  CHIEF MEDICAL OFFICER
• William Fricker,
  Principal Accounting Officer
• Morris Rosenberg,
  Chief Technology Officer
• Charles M Baum,
  Director
• Bryan Ball,
  Chief Quality Officer
• Barbara Gayle Duncan,
  Director
• Kurt J. Andrews,
  Chief Human Resources Officer
• Ivan D Horak,
  EVP R&D & Ch. Scientific Off.
• Cynthia L Goldenberg,
  President and CEO
• Richard R Pivirotto,
  Director
• Don C Stark,
  Director
• Mary E Paetzold,
  Director
• Arthur S Kirsch,
  Director
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Richard L. Sherman,
  Director
• David M Goldenberg,
  Chairman & Ch. Strategic Off.
• Marcella Lo Castro,
  Director
• Edward T Wolynic,
  Director
• Morton Coleman,
  Director
• Gerard G Gorman,
  VP of Finance & CFO
• Kenneth J Zuerblis,
  Director
• Lorettta M Itri,
  Chief Medical Officer
• Robert Azelby,
  Director
• Usama Malik,
  Chief Fin. & Business Officer
• Brendan Delaney,
  Chief Commercial Officer
• Jared Freedberg,
  Gen. Counsel & Corp. Secretary